35 results found.

Macular Edema Clinical Trial using VEGF Trap-Eye (BAY86-5321); Laser photocoagulation

Bayer - Recruiting 18 years or older.
- A Randomized, Double Masked, Active Controlled, Phase III Study of the Efficacy and Safety of Repeated Doses of Intravitreal VEGF Trap Eye in Subjects With Diabetic Macular Edema.
VEGF Trap-Eye (BAY86-5321); Laser photocoagulation

Cystoid Macular Edema, Cataract, or Diabetes Mellitus Clinical Trial using Bromfenac; Dexamethasone; Bevacizumab; Triamcinolone Acetonide

Maastricht University Medical Center - Recruiting 21 years or older.
- PRevention of Macular EDema After Cataract Surgery.
Bromfenac; Dexamethasone; Bevacizumab; Triamcinolone Acetonide

Diabetic Macular Edema (DME) Clinical Trial

Alimera Sciences - Recruiting 18 years or older.
- ILUMINATE: An Open-Label, Non-Interventional Study of the Safety and Effect of Iluvien® (Fluocinolone Acetonide 190 Micrograms Intravitreal Implant in Applicator) in Patients With Chronic Diabetic Macular Edema (DME) Insufficiently Responsive to Available Therapies.

Diabetic Macular Edema Clinical Trial using Ranibizumab and Bevacizumab; Bevacizumab

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Phase II Randomized Study to Compare Anti-VEGF Agents in the Treatment of Diabetic Macular Edema (CADME).
Ranibizumab and Bevacizumab; Bevacizumab

Diabetic Macular Edema Clinical Trial using Dextromethorphan

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Pilot Phase I/II Study for the Evaluation of Dextromethorphan as a Microglia Inhibitor in the Treatment of Diabetic Macular Edema (MiDME2).
Dextromethorphan

Diabetic Macular Edema Clinical Trial using Ranibizumab 0.3mg/0.05cc

Southeast Retina Center, Georgia - Recruiting 18 years or older.
- Ranibizumab For Persistent Diabetic Macular Edema After Bevacizumab (ROTATE Trial).
Ranibizumab 0.3mg/0.05cc

Branch Retinal Vein Occlusion Clinical Trial using Ranibizumab 0.5 mg; Sham injection

Novartis - Recruiting N/A or older.
- A Randomized Double-masked, Phase III Study Assessing Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Visual Impairment Due to Macular Edema (ME) Secondary to Branch Retinal Vein Occlusion (BRVO) [Blossom].
Ranibizumab 0.5 mg; Sham injection

Central Retinal Vein Occlusion Clinical Trial using Sham injection; Ranibizumab 0.5 mg

Novartis - Recruiting N/A or older.
- A Randomized Double-masked, Phase III Study Assessing Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Visual Impairment Due to Macular Edema (ME) Secondary to Central Retinal Vein Occlusion (CRVO) [Camellia].
Sham injection; Ranibizumab 0.5 mg

Diabetic Retinopathy, or Macular Edema Clinical Trial using Tromethamine ketorolac; Nepafenac; Polietilenglicol 400, propilenglicol, HP guar

Hospital Juarez de Mexico - Recruiting 40 years to 80 years.
- Efficacy of Topic Antiinflammatory Therapy Treatment in Center Point Thickness Secondary to Selective Photocoagulation in Diabetic Macular Edema.
Tromethamine ketorolac; Nepafenac; Polietilenglicol 400, propilenglicol, HP guar

Proliferative Diabetic Retinopathy, or Macular Edema Clinical Trial using Ketorolac tromethamine; Alcohol polivinilico

Hospital Juarez de Mexico - Recruiting 40 years to 75 years.
- Efficacy and Safety of Topic Ketorolac to Treat Center Point Thickness Secondary to Panphotocoagulation in Proliferative Diabetic Retinopathy.
Ketorolac tromethamine; Alcohol polivinilico

Macular Edema, Diabetic Clinical Trial using Ranibizumab; Placebo; PF-04634817; Masked Sham Therapy

Pfizer - Recruiting 18 years or older.
- A Phase 2, Randomized, Double-Masked, Placebo-Controlled, Parallel Group, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist (PF-04634817) With That Of Ranibizumab In Adult Subjects With Diabetic Macular Edema.
Ranibizumab; Placebo; PF-04634817; Masked Sham Therapy

Retinal Vein Occlusion, or Macular Edema Clinical Trial using Anti-VEGF

Allergan - Recruiting 18 years or older.
- .
Anti-VEGF

Retinal Vein Occlusion Clinical Trial using RFB002; Dexamethasone

Novartis - Recruiting 18 years or older.
- An Open-label, Multi-center, 6-month Extension Study Comparing the Long-term Efficacy and Safety of Lucentis (Ranibizumab) Intravitreal Injections Versus Ozurdex (Dexamethasone) Intravitreal Implant in Patients With Visual Impairment Due to Macular Edema Following Branch Retinal Vein Occlusion (BRVO) or Central Retinal Vein Occlusion (CRVO) Who Have Completed the Respective Core Study (CRFB002EDE17 or CRFB002EDE18).
RFB002; Dexamethasone

Macular Edema, or Retinal Vein Occlusion Clinical Trial using dexamethasone implant

Allergan - Recruiting 18 years or older.
- .
dexamethasone implant

Macular Edema, or Central Retinal Vein Occlusion Clinical Trial using Ranibizumab 0.5 mg/0.05 ml, intravitreal injection

Novartis - Recruiting 18 years or older.
- A 24-month, Phase IIIb, Open-label, Single Arm, Multicenter Study Assessing the Efficacy and Safety of an Individualized, Stabilization-criteria-driven PRN Dosing Regimen With 0.5-mg Ranibizumab Intravitreal Injections Applied as Monotherapy in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal.
Ranibizumab 0.5 mg/0.05 ml, intravitreal injection

Macular Edema (ME) Clinical Trial using Sham control; Ranibizumab

Novartis - Recruiting 12 years or older.
- A 12-month, Randomized, Double-masked, Sham-controlled, Multicenter Study to Evaluate the Efficacy and Safety of 0.5mg Ranibizumab Intravtitreal Injections in Patients With Visual Impairment Due to VEGF-driven Macular Edema.
Sham control; Ranibizumab

Choroidal Neovascularization, Macular Edema, Glaucoma, Neovascula Clinical Trial using ranibizumab

Novartis - Recruiting 18 years or older.
- An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases..
ranibizumab

Clinically Significant Macular Edema Clinical Trial using Navigated laser; Anti-VEGF Injections

OD-OS GmbH - Recruiting 18 years or older.
- .
Navigated laser; Anti-VEGF Injections

Diabetic Macular Edema Clinical Trial

Medical University of Vienna - Recruiting 18 years or older.
- The Influence of Retinal Oxygenation on the Clinical Outcomes in Eyes With Different Vitreoretinal Pathologies After a Successful Vitrectomy.

Ophthalmology, Macular Edema, or Macular Degeneration Clinical Trial using Ranibizumab (or other DME treatment)

Bayer - Recruiting N/A or older.
- POLARIS: A Non-interventional Study in Patients With Diabetic Macular Edema (DME) With Central Involvement to Assess the Effectiveness of Existing Anti-vascular Endothelial Growth Factor (Anti-VEGF) Treatment Regimens.
Ranibizumab (or other DME treatment)

Non-Proliferative Diabetic Retinopathy, or Cataract Clinical Trial using Nepafenac Ophthalmic Suspension, 0.3%; Nepafenac Vehicle; Prednisolone acetate ophthalmic suspension

Alcon Research - Recruiting 18 years or older.
- Randomized, Double-Masked, Vehicle Controlled, Clinical Evaluation To Assess The Safety And Efficacy Of Nepafenac Ophthalmic Suspension, 0.3% For Improvement In Clinical Outcomes Among Diabetic Subjects Following Cataract Surgery.
Nepafenac Ophthalmic Suspension, 0.3%; Nepafenac Vehicle; Prednisolone acetate ophthalmic suspension

Non-Proliferative Diabetic Retinopathy, or Cataract Clinical Trial using Nepafenac Ophthalmic Suspension, 0.3%; Nepafenac vehicle; Prednisolone acetate ophthalmic suspension

Alcon Research - Recruiting 18 years or older.
- Randomized, Double-Masked, Vehicle Controlled, Clinical Evaluation To Assess The Safety And Efficacy Of Nepafenac Ophthalmic Suspension, 0.3% For Improvement In Clinical Outcomes Among Diabetic Subjects Following Cataract Surgery.
Nepafenac Ophthalmic Suspension, 0.3%; Nepafenac vehicle; Prednisolone acetate ophthalmic suspension

Macular Edema, or CNV Clinical Trial

University Hospital Inselspital, Berne - Recruiting 18 years or older.
- Evaluation of Retinal Structure With High Resolution OCT.

Proliferative Diabetic Retinopathy, or Macular Edema Clinical Trial using laser treatment with PASCALr; laser treatment with conventional laser system

Medical University of Vienna - Recruiting 18 years to 90 years.
- Morphological and Functional Retinal Changes Following Retinal Photocoagulation Using a Semiautomated Patterned Scanning Laser System in Proliferative Retinopathy or Macular Edema Secondary to Diabetes Mellitus or Retinal Vein Occlusion.
laser treatment with PASCALr; laser treatment with conventional laser system

Epiretinal Membrane, or Macular Edema Clinical Trial using Dexamethasone Intravtireal Implant

Barnes Retina Institute - Recruiting N/A or older.
- Dexamethasone Intravitreal Implant After Vitrectomy for Idiopathic Epiretinal Membrane.
Dexamethasone Intravtireal Implant

Macular Edema After Cataract Surgery in Patients With Diabetes Me Clinical Trial using Dexamethasone intravitreal implant; Steroid plus NSAID eye drop combination therapy

Retinal Consultants of Arizona - Recruiting 18 years or older.
- A 3-Month Clinical Trial to Assess the Safety and Efficacy of the OZURDEXr Intraocular Implant in Patients With Diabetes Mellitus.
Dexamethasone intravitreal implant; Steroid plus NSAID eye drop combination therapy

Macular Edema Following Branch Retinal Vein Occlusion Clinical Trial using Betamethasone Microsphere (DE-102) Low Dose; Betamethasone Microsphere (DE-102) High Dose; Sham

Santen Pharmaceutical Co., Ltd. - Recruiting 20 years or older.
- A Randomized, Sham Controlled, Multicenter, Double-Masked, Phase 2/3 Study Assessing Efficacy and Safety of Betamethasone Microsphere in Patients With Macular Edema Following Branch Retinal Vein Occlusion.
Betamethasone Microsphere (DE-102) Low Dose; Betamethasone Microsphere (DE-102) High Dose; Sham

Diabetic Macular Edema Clinical Trial using Ranibizumab; Bevacizumab

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) - Recruiting 18 years or older.
- Comparing the Effectiveness and Costs of Bevacizumab to Ranibizumab in Patients With Diabetic Macular Edema (The BRDME Study).
Ranibizumab; Bevacizumab

Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, or Clinical Trial using ranibizumab 0.5mg; ranibizumab 1.0mg

Hanscom, Thomas, M.D. - Recruiting 18 years or older.
- Phase I/II, Open-label, Study of Intravitreal RAnibizumab 0.5MG, or High Dose 1.0mg for Retinal Vein Occlusions With rEfractory Macular Edema Previously Receiving iNtravitreal Bevacizumab (RAVEN).
ranibizumab 0.5mg; ranibizumab 1.0mg

Diabetic Macular Edema Clinical Trial using Bevacizumab intravitreal; Triamcinolone; Triamcinolone + Bevacizumab

Federal University of Sao Paulo - Recruiting 18 years or older.
- A Randomized, Parallel Group, Masked Clinical Study to Evaluate the Efficacy of Triamcinolone and Bevacizumab Through Intravitreal Injection With Individual or Simultaneous Drugs to Treatment of Diabetic Macular Edema.
Bevacizumab intravitreal; Triamcinolone; Triamcinolone + Bevacizumab

Diabetic Macular Edema, or Pars Plana Vitrectomy Clinical Trial using SAR 1118 0.1%; SAR 1118 1.0%; SAR 1118 5.0%

Johns Hopkins University - Recruiting 18 years or older.
- A Phase 1b, Randomized, Uncontrolled, Single-masked, Safety, Tolerability, and Pharmacokinetic Study of Multiple Doses of Three Different Concentrations (0.1%, 1.0%, 5.0%) of SAR 1118 Ophthalmic Solution in Human Subjects Undergoing Elective Pars Plana Vitrectomy (PPV).
SAR 1118 0.1%; SAR 1118 1.0%; SAR 1118 5.0%

Diabetic Macular Edema Clinical Trial using Infliximab (intravitreal, 2.0mg/0.05ml)

Mount Sinai School of Medicine - Recruiting 18 years or older.
- Pilot Study for the Evaluation of Intravitreal Infliximab in the Treatment of Diabetic Macular Edema.
Infliximab (intravitreal, 2.0mg/0.05ml)

Macular Thickening, or Macular Edema Clinical Trial using Nepafenac; Lubricant

Asociaci¢n para Evitar la Ceguera en M‚xico - Recruiting 18 years or older.
- Effect of Topical Nepafenac in Macular Thickening Related to Pan-Retinal Photocoagulation.
Nepafenac; Lubricant

Diabetic Macular Edema Clinical Trial using Laser photocoagulation

Federal University of Sao Paulo - Recruiting 18 years or older.
- Phase 2 Study of Micropulse 810nm Diode Laser Photocoagulation for Treatment of Diffuse Diabetic Macular Edema.
Laser photocoagulation